Key result
Aldactone successfully treated a patient with malignant hypertension and thrombotic microangiopathy, highlighting that laboratory tests may obscure the primary cause of hypertension in such cases.
Case Report (n=1)
In cases of malignant hypertension with thrombotic microangiopathy, laboratory tests may reflect microangiopathic hemolytic anemia outcomes, complicating the identification of the primary cause of hypertension.
Answers are grounded in this paper and cite their sources.
Spironolactone may aid select malignant hypertension cases with TMA; hypothesis-generating and should not yet change practice.
We represented a case of malignant hypertension with thrombotic microangiopathy. There was found no finding revealing renovascular hypertension inspite of high renin and aldosterone levels. The patient responded to aldactone that was administered because of the likelihood of primary aldosteronism regarding the causes of secondary hypertension. We aimed to point out that the laboratory tests may reflect the outcomes of microangiopathic hemolytic anemia; therefore in such circumstances it may be impossible to find out the main reason of hypertension
No takes yet. Share an insight, caveat, or question.
Baştürk et al. (2015) conducted a case report in Malignant hypertension with thrombotic microangiopathy (n=1). Aldactone was evaluated. Aldactone successfully treated a patient with malignant hypertension and thrombotic microangiopathy, highlighting that laboratory tests may obscure the primary cause of hypertension in such cases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: